ClearSpec LLC 510(k) Notification Submission

510(k) Summary

Date: July 23, 2013

Submitted by:

ClearSpec LLC

131 NW 13th Street, Suite 38 Boca Raton, FL 33432

Phone:

561-395-7767

Fax:

561-237-5040

Contact:

Navroze Mehta

Common Name:

Vaginal Speculum

Trade Name:

ClearSpec® Single-Use Vaginal Speculum

AUG 0 6 2013

Classification

Name:

Speculum, Vaginal, Nonmetal

Classification:

Class II per 21 CFR 884.4530, Product Code: HIB

Predicate Device:

Gongdong Disposable Vaginal Speculum (K050887)

Welch Allyn KleenSpec® Single Use Vaginal Speculum (K120743)

Device Description:

The ClearSpec® Single Use Vaginal Speculum is a disposable vaginal speculum constructed of polystyrene, used to dilate the vagina and expose the interior of the vagina and exterior of the cervix, and employs a unique flexible polyurethane sheath that is designed to assist in keeping the lateral walls of the vagina clear of the viewing area. The vaginal speculum can be used with or without an illuminator.

The ClearSpec® Single Use Vaginal Speculum is made available in various sizes from extra small to large to accommodate vagina cavity size.

Indications for Use:

The ClearSpec® Single-Use Vaginal Speculum is used to dilate the vagina and expose the interior of the vagina and exterior of the cervix during pelvic examinations and other gynecological procedures.

Technological Characteristics:

The subject device has the same technological characteristics and indications for use as the predicate Gongdong Disposable Vaginal Speculum and Welch Allyn KleenSpec® Single Use Vaginal Speculum. The addition of a sheath surrounding the device blades to aid in retaining lateral vaginal tissue does not introduce any new concerns regarding safety or effectiveness. The designs have been demonstrated as substantial equivalent using bench testing.

5-2 ClearSpec LLC 510(k) Notification Submission

The ClearSpec® Single-Use Vaginal Speculum and identified predicate devices are constructed of similar material commonly used throughout the medical device industry for like and similar devices and have been tested for biocompatibility per FDA GPM G95-1 and ISO 10993-1 requirements for limited contact duration, surface contacting mucousal membrane device and found to be suitable for the intended use of this product.

Intended Use:

The ClearSpec® Single-Use Vaginal Speculum is used to dilate the vagina and expose the interior of the vagina and exterior of the cervix during pelvic examinations and other gynecological procedures.

Testing:

Bench testing has been conducted using simulated actual use conditions comparing the new device with the addition of the sheath to that of original speculum without the sheath. The results of the testing show the new device to perform as intended and equivalent to the predicate device. Testing included sheath material ability to survive stresses encountered during use without failure and sufficiency of sheath to speculum bond strength such that the sheath does not detach from the speculum during insertion, during the examination, or during withdrawal.

Conclusion:

In accordance with the Food, Drug, and Cosmetic Act and 21 CFR 807, and based on the information provided in the premarket notification application, ClearSpec LLC concludes that the ClearSpec® Single-Use Vaginal Speculum is substantially equivalent to the predicate device in terms of safety and effectiveness.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

August 6, 2013

ClearSpec, LLC % Ira Duesler Consultant 603 Grant Street Herkimer, NY 13350

Re: K130046

Trade/Device Name: ClearSpec® Single-Use Vaginal Speculum

Regulation Number: 21 CFR§ 884.4530

Regulation Name: Obstetric-gynecologic specialized manual instrument

Regulatory Class: II Product Code: HIB Dated: July 8, 2013 Received: July 9, 2013

Dear Ira Duesler,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,



for

Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications For Use

| 5 IU(K) Number: | K130046 | | |
|--|---|-------------------|--|
| Device Name: | ClearSpec® Single-U | Jse Vaginal Spe | eculum |
| Indications For Use: | | | · |
| expose the in | ec [®] Single-Use Vagir terior of the vagina an and other gynecologi | d exterior of the | |
| Prescription Device _ (Part 21 CFR 801 Subpar | | D/OR | Over-The-Counter(21 CFR 801 Subpart C) |
| (PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED) | | | |
| Concurrence of CDRH, Office of Device Evaluation (ODE) | | | |

Glenn B. Bell -S

(Division Sign-Off)
Division of Reproductive, Gastro-Renal, and Urological Devices
510(k) Number K130046